Clinical Trial Results: A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety, tolerability, and levodopa pharmacokinetics of repeated ND0612 in Parkinson's disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 (ND0612)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-07-09